Nature Medicine· Jia Xu·· 2026-10-06AI 评分23
体内 BCMA CAR-T 治疗复发/难治性多发性骨髓瘤的延长随访
Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma
AI 导读
4例复发/难治性多发性骨髓瘤患者接受体内 BCMA CAR-T 细胞治疗后,延长随访显示3例缓解持续时间有限,1例持续缓解至15个月。研究发表于 Nature Medicine。
正文
Nature Medicine, Published online: 06 October 2026; doi:10.1038/s41591-026-04704-z
Extended follow-up of four patients with multiple myeloma treated with in vivo BCMA CAR-T cells showed limited duration of response in three patients, while one patient had sustained response to 15 months.
来源:Nature Medicine · nature.com